Trial Profile
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Moxr0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Vonlerolizumab (Primary) ; Atezolizumab
- Indications Urogenital cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 30 May 2019 Status changed from completed to discontinued.
- 10 May 2018 Status changed from active, no longer recruiting to completed.